Roche is poised to expand its global cancer diagnostics product offering by entering into an agreement to acquire the German in vitro diagnostics company mtm laboratories for €190 M (US$267 M). The acquisition will provide Roche with a complementary portfolio of cervical cancer diagnostics, including CINtec® PLUS Cytology for the detection of precancerous lesions and the CINtec Histology Kit for the identification of high-grade cervical intraepithelial neoplasia and cervical carcinoma in biopsy samples.